Wedbush Securities has lowered its price target for BioMarin Pharmaceutical to $89 from $94, while maintaining an Outperform rating. This adjustment follows the company's Q3 2026 earnings release and updated financial expectations, suggesting a slightly less optimistic outlook from the analyst.
Wedbush Securities reduced its price target for BioMarin Pharmaceutical (BMRN) from $94 to $89. This change occurred after BioMarin's Q3 2026 earnings release, which included updated financial expectations for the remainder of the year. While the Outperform rating was maintained, the lower price target indicates that Wedbush sees slightly less upside potential for the stock in the near term. This could lead to some negative sentiment among investors, as analyst price target adjustments often influence trading decisions. For traders, this presents a short-term headwind, though the maintained Outperform rating suggests long-term confidence in the company's fundamentals.